[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337635-105":59,"doc-detail-337635-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","synchronous-papillary-thyroid-cancer-and-colorectal-cancer-in-a-young-patient-with-a-chek2-mutation","Synchronous Papillary Thyroid Cancer and Colorectal Cancer in a Young Patient with a CHEK2 Mutation","","Mutations of CHEK2 are typically inherited and have been linked to multiple cancers, acting through the ATM-CHEK2-p53 pathway to respond to DNA double-strand breaks. This case report details a 29-year-old Canadian woman with synchronous papillary thyroid carcinoma and rectal adenocarcinoma who was found to carry a sporadic CHEK2 (checkpoint kinase 2) mutation. She initially presented with bright red blood per rectum and later underwent colonoscopy and staging, followed by genetic panel testing. The patient received neoadjuvant brachytherapy and surgery with a favorable response, highlighting the rarity of simultaneous colorectal and papillary thyroid cancers under age 30 without family history.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/synchronous-papillary-thyroid-cancer-and-colorectal-cancer-in-a-young-patient-with-a-chek2-mutation/337635/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/synchronous-papillary-thyroid-cancer-and-colorectal-cancer-in-a-young-patient-with-a-chek2-mutation/337635.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the role of CHEK2 in cancer susceptibility?","Question",{"text":112,"@type":113},"CHEK2 encodes checkpoint kinase 2, an effector in the ATM-CHEK2-p53 pathway that responds to DNA double-strand breaks. Germline CHEK2 mutations are associated with multi-organ cancer susceptibility.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the patient initially present and how were the tumors identified?",{"text":117,"@type":113},"The patient reported an 8-month history of increasing bright red blood per rectum. After colonoscopy revealed a large rectal tumor, biopsy confirmed invasive rectal adenocarcinoma, and subsequent thyroid evaluation showed a synchronous papillary thyroid carcinoma.",{"name":119,"@type":110,"acceptedAnswer":120},"What did genetic testing reveal and how was the patient treated?",{"text":121,"@type":113},"A genetic panel identified a low-risk CHEK2 mutation. The rectum was treated with neoadjuvant brachytherapy and both cancers were managed surgically, with a full response reported.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337635,1790798493,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Case Reports in Oncology  \n\n| Case Rep Oncol 2024;17:524–531 |  |\n| --- | --- |\n| DOI: 10.1159/000536052\u003Cbr>Received: November 14, 2023\u003Cbr>Accepted: December 27, 2023\u003Cbr>Published online: April 2, 2024 | © 2024 The Author(s) .\u003Cbr>Published by S. Karger AG, Basel [www.karger.com/cro](www.karger.com/cro) |\n\nThis article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ([http://www.karger.com/Services/OpenAccessLicense](http://www.karger.com/Services/OpenAccessLicense)). Usage and distribution for commercial purposes requires written permission.  \nCase Report  \nSynchronous Papillary Thyroid Cancer and Colorectal Cancer in a Young Patient with a CHEK2 Mutation  \nSydney Brooke Hoskins Leslie Torgerson  \nDepartment of Biomedical Sciences, Rocky Vista University College of Osteopathic Medicine, Greenwood Village, CO, USA  \nKeywords  \nCHEK2 · Colorectal cancer · Papillary thyroid cancer · Synchronous tumors  \nAbstract  \nIntroduction: Mutations of CHEK2 are usually inherited and have been implicated in breast cancers, colorectal cancers, thyroid cancers, kidney cancers, and prostate cancers. The CHEK2 gene codes for checkpoint kinase 2 protein which is an effector in the ATM-CHEK2-p53 pathway and responds to DNA double-strand breaks. Case Presentation: We describe a unique case of a 29-year-old Canadian female who presented with synchronous papillary thyroid carcinoma and rectal adenocarcinoma who was subsequently found to have a sporadic CHEK2 (checkpoint kinase 2) mutation. She presented with an 8-month history of bright red blood per rectum and saw two different physicians who diagnosed hemorrhoids and possible rectal ulcers, respectively. When the symptoms continued, the patient pursueda colonoscopy exam which found a large rectal tumor. Subsequent clinical staging diagnosed a rectal adenocarcinoma and a synchronous papillary thyroid carcinoma. Due to her synchronous tumors, a genetic panel was performed, which revealed a low-risk CHEK2 mutation. Our patient had a full response to neoadjuvant brachytherapy of the rectum and surgical treatment of her cancers. Conclusion: This is the ﬁrst case report, to our knowledge, of a patient with a CHEK2 mutation who presented with synchronous papillary thyroid carcinoma and invasive colonic adenocarcinoma. The incidence of colorectal cancers and papillary thyroid cancers in those under 30 with no family history is very low, which signiﬁes the rarity of their simultaneous occurrence at such a young age.  \n© 2024 The Author(s) .  \nPublished by S. KargerAG, Basel  \nCorrespondence to:  \nSydney Brooke Hoskins, [sydneyhoskins23](sydneyhoskins23@ gmail.com)[@](sydneyhoskins23@ gmail.com)[ gmail.com](sydneyhoskins23@ gmail.com)  \nCase Reports in Oncology  \nCase Rep Oncol 2024;17:524–531 525  \n\n| DOI: 10.1159/000536052 | © 2024 The Author(s) . Published by S. Karger AG, Basel [www.karger.com/cro](www.karger.com/cro) |\n| --- | --- |\n\nHoskins and Torgerson: CHEK2 Synchronous Tumors  \nIntroduction  \nWe describe a case of a female with synchronous presentation of rectal adenocarcinoma and papillary thyroid carcinoma with neck node metastasis at the age of 29 years. Given her young age at presentation and synchronous tumors, genetic studies were performed, and CHEK2 mutation was discovered. The CHEK2 gene codes for checkpoint kinase 2 protein which is an effector in the ATM-CHEK2-p53 pathway [1]. It responds to DNA double strand breaks and serves as a tumor suppressor gene. CHEK2 mutations are frequently seen as germline mutations and are associated with multi-organ cancer susceptibility. CHEK2 testing is routinely done when hereditary cancers are suspected as part of genetics panels [2]. Colorectal cancer is increasing in incidence, and it has been shown that many patients with colorectal cancer have multiple primary cancers. Lee et al. [3] found that 36.4% of patients with colorectal cancer had a synchronous primary tumor. Of these, thyroid cancer was ","cbCaikh5KfIRumuk","https://ap.wps.com/l/cbCaikh5KfIRumuk","pdf",1180730,"English","# Introduction\n# Case Presentation\n## Patient history and diagnostic workup\n## Treatment and outcomes\n# Conclusion","[{\"question\":\"What is the role of CHEK2 in cancer susceptibility?\",\"answer\":\"CHEK2 encodes checkpoint kinase 2, an effector in the ATM-CHEK2-p53 pathway that responds to DNA double-strand breaks. Germline CHEK2 mutations are associated with multi-organ cancer susceptibility.\"},{\"question\":\"How did the patient initially present and how were the tumors identified?\",\"answer\":\"The patient reported an 8-month history of increasing bright red blood per rectum. After colonoscopy revealed a large rectal tumor, biopsy confirmed invasive rectal adenocarcinoma, and subsequent thyroid evaluation showed a synchronous papillary thyroid carcinoma.\"},{\"question\":\"What did genetic testing reveal and how was the patient treated?\",\"answer\":\"A genetic panel identified a low-risk CHEK2 mutation. The rectum was treated with neoadjuvant brachytherapy and both cancers were managed surgically, with a full response reported.\"}]","Synchronous Papillary Thyroid Cancer and Colorectal Cancer in a Young Patient with a CHEK2 Mutation | PDF",1790019918,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aad2c87b207c2e195309589776c0a89f.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d1245fb3546a498397a37207b3a0a96.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e27ec58382f2e43470c5097dbb48b18f.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b93a09b054db879bb1b6b8c5b6077ccc.webp",980,1306]